| Lead author [ref.] | Site (year) | TST | Cases/number treated# | RR (95% CI)¶ | |||||
| H | HR | RZ(H) | R | HR | RZ(H) | R | |||
| Whalen 99 | Uganda (1997) | Positive | 7/536§ | 9/556 | 10/462ƒ | 0.81 (0.30–2.15) | 0.60 (0.23–1.57) | ||
| Mwinga 102 | Zambia (1998) | Positive | 4/52## | 2/49¶¶ | 1.88 (0.36–9.83) | ||||
| Negative | 14/178## | 13/173¶¶ | 1.05 (0.51–2.16) | ||||||
| Unknown | 9/122## | 10/129¶¶ | 0.95 (0.40–2.26) | ||||||
| Halsey 111 | Haiti (1998) | Positive | 14/370## | 19/380§§ | 0.76 (0.39–1.49) | ||||
| Martinez 112 | Spain (2000) | Positive | 3/21++ | 1/26 | 3.71 (0.42–33.15) | ||||
| Negative | 1/43++ | 1/43 | 1.00 (0.06–15.48) | ||||||
| Gordin 113 | International (2000) | Positive | 29/792++ | 28/791ƒƒ | 1.03 (0.62–1.72) | ||||
| Rivero 104 | Spain (2003) | Anergic | 3/83§ | 3/82 | 1/77ƒƒ | 0.99 (0.21–4.75) | 0.70 (0.16–3.05) | ||
| Rivero 114 | Spain (2007) | Positive | 4/108§ | 5/103 | 2/105ƒƒ | 0.76 (0.21–2.76) | 1.94 (0.36–10.39) | ||
| Girling 73+ | Hong Kong (1992) | Positive### | 20/100§ | 19/87 | 17/103 | 0.92 (0.52–1.60) | 1.21 (0.68–2.18) | ||
TST: tuberculin skin test; RR: risk ratio; H: isoniazid for 6–12 months; HR: isoniazid and rifampicin daily for 3 months; RZ(H): rifampicin plus pyrazinamide or rifampicin plus pyrazinamide plus isoniazid for 2–3 months; R: rifampicin daily for 3 months. #: active TB cases within 1–5 yrs of follow-up (variable and with considerable attrition); ¶: isoniazid versus regimen; +: non-HIV; §: isoniazid daily for 6 months; ƒ: isoniazid plus rifampicin plus pyrazinamide daily for 3 months; ##: isoniazid twice weekly for 6 months; ¶¶: rifampicin plus pyrazinamide twice weekly for 3 months; ++: isoniazid daily for 12 months; §§: rifampicin plus pyrazinamide twice weekly for 2 months; ƒƒ: rifampicin plus pyrazinamide daily for 2 months; ###: mainly TST-positive.